Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
23
IRWD Quote, Financials, Valuation and Earnings
Last price:
$3.40
Seasonality move
:
-3.4%
Day range:
$3.22 - $3.56
52-week range:
$0.53 - $5.78
Dividend yield:
0%
P/E ratio:
30.35x
P/S ratio:
2.09x
P/B ratio:
--
Volume:
6.8M
Avg. volume:
3.2M
1-year change:
114.04%
Market cap:
$595.4M
Revenue:
$296.2M
EPS (TTM):
$0.12
Analysts' Opinion
-
Consensus RatingIronwood Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $5.35, Ironwood Pharmaceuticals, Inc. has an estimated upside of 46.18% from its current price of $3.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.70 representing 80.87% downside risk from its current price of $3.66.
Fair Value
-
According to the consensus of 3 analysts, Ironwood Pharmaceuticals, Inc. has 46.18% upside to fair value with a price target of $5.35 per share.
IRWD vs. S&P 500
-
Over the past 5 trading days, Ironwood Pharmaceuticals, Inc. has underperformed the S&P 500 by -20.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ironwood Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ironwood Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ironwood Pharmaceuticals, Inc. reported revenues of $47.7M.
Earnings Growth
-
Ironwood Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ironwood Pharmaceuticals, Inc. reported earnings per share of -$0.01.
Enterprise value:
977.7M
EV / Invested capital:
2.91x
Price / LTM sales:
2.09x
EV / EBIT:
8.23x
EV / Revenue:
3.30x
PEG ratio (5yr expected):
0.03x
EV / Free cash flow:
14.45x
Price / Operating cash flow:
9.47x
Enterprise value / EBITDA:
8.10x
Gross Profit (TTM):
$294.3M
Return On Assets:
6.62%
Net Income Margin (TTM):
8.11%
Return On Equity:
--
Return On Invested Capital:
7.88%
Operating Margin:
13.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $442.7M | $351.4M | $296.2M | $90.5M | $47.7M | |
| Gross Profit | $441.2M | $349.4M | $294.3M | $90.1M | $47.2M | |
| Operating Income | $173.4M | $105.9M | $118.8M | $33.3M | $6.6M | |
| EBITDA | $175M | $108M | $120.6M | $33.8M | $7M | |
| Diluted EPS | -$6.51 | $0.01 | $0.12 | $0.02 | -$0.01 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $745.2M | $780.6M | $233.3M | $182.4M | $274.2M | |
| Total Assets | $1.1B | $1.1B | $471.1M | $350.9M | $396.9M | |
| Current Liabilities | $161.7M | $25.5M | $276.1M | $38.8M | $242.2M | |
| Total Liabilities | $521M | $448.1M | $817.4M | $652.2M | $658.7M | |
| Total Equity | $605.9M | $652.4M | -$346.3M | -$301.3M | -$261.8M | |
| Total Debt | $472.7M | $412.9M | $712.4M | $596.3M | $594.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $226.8M | $124.2M | $67.7M | $9.9M | $47.6M | |
| Cash From Investing | -$1B | -$4.3M | -$35K | -$16K | -$2K | |
| Cash From Financing | $330.9M | -$143M | -$14.8M | -$27.2M | -- | |
| Free Cash Flow | $226.7M | $123.8M | $67.6M | $9.9M | $47.6M | |
IRWD
Sector
Market Cap
$595.4M
$25.8M
Price % of 52-Week High
63.32%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
0.61%
-1.64%
1-Year Price Total Return
114.04%
-18.88%
Beta (5-Year)
0.172
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$4.09
200-day SMA
Buy
Level
$2.12
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$4.43
Relative Strength Index (RSI14)
Sell
Level
35.18
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-63.6829
50-day SMA
Sell
Level
$4.22
MACD (12, 26)
Buy
Level
0.58
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.7281)
Sell
CA Score
(Annual)
Level (-4.4757)
Buy
Beneish M-Score
(Annual)
Level (-4.3298)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (7.1253)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, IRWD has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The IRWD average analyst price target in the past 3 months is $5.35.
-
Where Will Ironwood Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ironwood Pharmaceuticals, Inc. share price will rise to $5.35 per share over the next 12 months.
-
What Do Analysts Say About Ironwood Pharmaceuticals, Inc.?
Analysts are divided on their view about Ironwood Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ironwood Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $0.70.
-
What Is Ironwood Pharmaceuticals, Inc.'s Price Target?
The price target for Ironwood Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $5.35 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is IRWD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ironwood Pharmaceuticals, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IRWD?
You can purchase shares of Ironwood Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ironwood Pharmaceuticals, Inc. shares.
-
What Is The Ironwood Pharmaceuticals, Inc. Share Price Today?
Ironwood Pharmaceuticals, Inc. was last trading at $3.40 per share. This represents the most recent stock quote for Ironwood Pharmaceuticals, Inc.. Yesterday, Ironwood Pharmaceuticals, Inc. closed at $3.66 per share.
-
How To Buy Ironwood Pharmaceuticals, Inc. Stock Online?
In order to purchase Ironwood Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IRWD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IRWD
Sector
P/E ratio
30.35x
23.44x
PEG ratio
0.03x
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
2.09x
1.56x
Growth Metrics
IRWD
Sector
Revenue growth
-47.31%
3.27%
Earnings growth
-170.35%
9.66%
Revenue (5-year growth)
-5.33%
6.43%
Earnings forecast
$0.01
-$0.20
Profitability
IRWD
Sector
Profitability FY 2025
$294.3M
$2.3M
Return on invested capital
7.88%
-33.49%
Return on assets
6.62%
-29.74%
Return on equity
--
-39.33%
Earnings Date
Last Earnings Date
Feb
25
Next Earnings Date
May
7
Estimated Next Earnings Date
May
27
Balance Sheet
IRWD
Sector
Total cash
$215.5M
$24.2M
Short term investments
--
$23.8M
Total assets
$396.9M
$71.1M
Long term debt
$594.6M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
